Antiarrhythmic drugs.

Slides:



Advertisements
Similar presentations
Normal ECG waves & ARRYHTHMIAS
Advertisements

By Dr.Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U.
The electrocardiogram (ECG or EKG)
TACHYCARDIAS Dr Kirsten Cohen
ARRHYTHMIAS TACHYCARDIA>100/min BRADYCARDIA
Or Doing Drugs for Your Heartbeat
Aims Introduction to the heart.
Anti-arrhythmic drugs
Na+ channel blocker: Na+ channel block depends on: HR
Mechanisms of cardiac arrhythmias
ANTIARRHYTHMIC DRUGS Arrhythmia or dysrhythmia means an abnormal or irregular heart beat Arrhythmias may originate in the atria, SA node or AV node, whereby.
ANTIARRHYTHMIC DRUGS Arrhythmia/ dysrhythmia means an abnormal or irregular heart beat Arrhythmias may originate in the atria, SA node or AV node, whereby.
Cardiac Arrhythmias.
Drugs used to treat cardiac arrhythmias
Anti-arrhythmic drugs
Anti arrhythmic Drugs Marwa A. Khairy , MD.
Antiarrhythmic drugs Pharma team.
Properties of Cardiac Muscle
ANTIARRHYTHMIC DRUGS 1. INTRODUCTION The heart contains specialized cells that exhibit automaticity; that is, they can generate rhythmic action potentials.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 49 Antidysrhythmic Drugs.
Section 2 Electrophysiology of the Heart
ANTIARRHYTHMIC DRUGS Department of Pharmacology and Toxicology
© Assoc. Prof. Ivan Lambev
Section 3, Lecture 4 Antiarrhytmic drugs cont…
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 23 Antiarrhythmic Drugs.
Arrhythmias and Antiarrhythmic Drugs
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 23 Antidysrhythmic Drugs.
Circus Movement Classification of antiarrhythmic drugs According to Vaughn-Williams Classification: Class 1: Sodium channel blockersClass 1: Sodium.
Antiarrhythmic Agents. BACKGROUND Inside cell: K + ; Outside cell: Na +, Ca + +, Cl - Action potential (AP) and Phase 0-4 phase0---reactivity---conduction---
ANTIARRHYTHMIC DRUGS 1. INTRODUCTION The heart contains specialized cells that exhibit automaticity; that is, they can generate rhythmic action potentials.
Chapter Goals After studying this chapter, students should be able to describe the general functions of the major components of the heart. 2. describe.
Cardiovascular pharmacology.
Cardiac electrical activity
The Electrical System of the Heart. Cardiac Muscle Contraction Depolarization of the heart is rhythmic and spontaneous About 1% of cardiac cells have.
Department faculty and hospital therapy of medical faculty and department internal diseases of medical prophylactic faculty. Cardiac arrhythmia Docent.
4-ANTIARRHYTHMIC DRUGS
Lecture Objectives Describe sinus arrhythmias Describe the main pathophysiological causes of cardiac arrhythmias Explain the mechanism of cardiac block.
Cardiovascular Block Cardiac Electric Activity
BIMM118 Cardiac Arrhythmia Arrhythmias : Abnormal rhythms of the heart that cause the heart to pump less effectively Arrhythmia occurs: –when the heart’s.
Electrical Activity of Heart & ECG
23 Antiarrhythmic Drugs.
MECHANISMS OF CARDIAC ARRHYTHMIAS. DR AMNA TAHIR PHYSIOLOGY DEPARTMENT. KEMU.
Antiarrhythmic Drugs. Drug List Class 1 Sodium Channel Blockers Class 2 Beta-blockers Class 3 Potassium Channel blockers Class 4 Calcium Channel Blockers.
Arrhythmias. Cardiac dysrhythmia Cardiac dysrhythmia (arrhytmia) Abnormal electrical activity in the heart.
ANTI-ARRHYTHMIC DRUGS
ACTION POTENTIAL CHARACTERISTICS OF SPECIALIZED CELLS
Dr. Mona Soliman, MBBS, MSc, PhD Associate Professor Department of Physiology Chair of Cardiovascular Block College of Medicine King Saud University.
Cardiac Arrhythmia.
1 CARDIAC ARRHYTHMIAS & ANTI-ARRHYTHMIC DRUGS Or Cardiac Dysrhythmias & Antidysrhythmic Drugs February, 2012.
Pharmacology 4 Dr. Khalil Makki. Antiarrhythmic Drugs.
Arrhythmia Arrhythmias are abnormal beats of the heart.
Prof. Abdulrahman Almotrefi
Lecture Objectives Describe sinus arrhythmias Describe the main pathophysiological causes of cardiac arrhythmias Explain the mechanism of cardiac block.
Antiarrhythmic Drugs.
Dept. of Pharmacology Faculty of Medicine AIMST
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 33 Disorders of Cardiac Conduction and Rhythm.
ARRHYTHMIAS Jamil Mayet. Arrhythmias - learning objectives –Mechanisms of action of antiarrhythmic drugs –Diagnosis To differentiate the different types.
Cardiovascular Cardiovascular pharmacology pharmacology.
RHYTHMICITY AND CONDUCTIVITY OF THE CARDIAC MUSCLE
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 25 Disorders of Cardiac Conduction and Rhythm.
Antidysrhythmic Agents
Antiarrhythmic Drugs 7/28/2018.
Cardiovascular System Block Cardiac Arrhythmias (Physiology)
CARDIAC ARRHYTHMIAS & ANTI-ARRHYTHMIC DRUGS
CVS Impulse generation
Antiarrhythmic drugs [,æntiə'riðmik] 抗心律失常药
Chapter 30 Antiarrhythmic Drugs
Antiarrhythmic Drugs Types of Cardiac Arrhythmias:
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family.
Drugs used in the treatment of arrhythmia I
Presentation transcript:

Antiarrhythmic drugs

Conducting system of the heart

Sequence of cardiac excitation Figure 12-11 The sinoatrial node is the heart’s pacemaker because it initiates each wave of excitation with atrial contraction. The Bundle of His and other parts of the conducting system deliver the excitation to the apex of the heart so that ventricular contraction occurs in an upward sweep.

Normal Sinus Rhythm Heart rhythm is determined by SA node = Cardiac Pacemaker Called sinus rhythm Specialised pacemaker cells spontaneously generate APs APs spread through the conducting pathways Normal sinus rate 60-100 beats/min

Conducting System SA Node AP triggers atrial depolarisation AV Nnode - Only pathway for AP to enter ventricles Conducts slowly: Complete atrial systole before ventricular systole Conducts rapidly through His Bundles & Purkinje – Ventricular depolarization & contraction

Conducting System Permits rapid organized depolarization of ventricular myocytes Necessary for the efficient generation of pressure during systole Atrial activation complete 0.09s after SAN firing Delay at AVN Septum activated 0.16s Whole ventricle activated by 0.23s

Cardiac Action Potential Phase 4: resting membrane potential AP depolarizes cells to threshold -70mV Phase 0: Rapid depolarization Caused by a transient opening of fast Na channels Increases inward directed depolarizing Na+ currents Generate "fast-response" APs

Cardiac Action Potential Phase 1: Initial repolarization Open K channel: transient outward hyperpolarizing K+ current Large increase in slow inward Ca++ occurs at the same time L-type Ca Ch open -40mV  Repolarization delayed Phase 2: Plateau phase Plateau phase prolongs AP duration vs APs in nerves and skeletal muscle

Cardiac Action Potential Phase 3: Repolarization K channels open Inactivation of Ca++ channels Action potential in non-pacemaker cells is primarily determined by relative changes in fast Na+, slow Ca++ and K+ conductances and currents

Refractory Periods Once an AP is initiated, there is a period (phase 0,1,2, part 3) that a new AP cannot be initiated. Effective or Absolute refractory period (ERP or ARP) Stimulation of cell by adjacent cell depolarizing does not produce new propagated APs Prevents compounded APs from occurring & limits frequency of depolarization and HR

SAN Pacemaker Potential Fully repolarized -60mv No stable Resting Membrane Potential Phase 4: Spontaneous depolarization or pacemaker potential Slow, inward Na+ channels open - "funny" currents Cause the membrane potential to begin to spontaneously depolarize During Ph4 there is also a slow decline in the outward movement of K+

SAN Pacemaker Potential -50mV T-type CaCh open Ca in: further depolarizes -40 mV L-type CaCh open More Ca in: further depol AP threshold -35mV Phase 0: Depolarization Primarily caused by Ca++ conductance through the L-type Ca++ channels Movement of Ca++ through these is slow so the rate of depolarization (Phase 0 slope) is slower than in other cardiac cells

SAN Pacemaker Potential Phase 3: Repolarization K+ channels open Increase the outward hyperpolarizing K+ currents At the same time the L-type Ca++ channels close gCa++ decreases Inward depolarizing Ca++ currents diminish Repolarization

Regulation of Cardiac APs SNS - Increased with concurrent inhibition vagal tone:  NA binds to B1 Rec Increases cAMP Increases Ca and Na in Decreases K out Increases slope phase 0 Non-Nodal tissue: More rapid depolarisation More forceful contraction Pacemaker current (If) enhanced  Increase slope phase 4 Pacemaker potential more rapidly reaches threshold Rate increased

Regulation of Cardiac APs PSNS (Vagal N) Ach binds M2 rec Increases gK+ Decreases inward Ca & Na Non-Nodal tissue: More rapid depolarisation More forceful contraction Pacemaker current (If) suppressed Decreases pacemaker rate Decrease slope of Phase 4 Hyperpolarizes in Phase 4 Longer time to reach threshold voltage

What is an Arrhythmia ? Irregular rhythm Abnormal Rate Conduction abnormality

What causes an arrhythmia? Changes in automaticity of the Pace Maker Ectopic foci causing abnormal Aps Excitable group of cells that causes a premature heart beat outside the normally functioning SA node of the human heart Hypoxic/Ischaemic tissue can undergo spontaneous depolarisation and become an ectopic pacemaker Reentry tachycardias Block of conduction pathways Abnormal conduction pathways (WPW) Electrolyte disturbances and DRUGS

Re-Entry Mechanism Branch 2 has a unidirectional block Impulses can travel retrograde (3 to 2) but not orthograde.  An AP will travel down the branch 1, into the common distal path (br 3), then travel retrograde through the unidirectional block in branch 2. When the AP exits the block, if it finds the tissue excitable, it will continue by traveling down (reenter) the branch 1. If it finds the tissue unexcitable (ERP) the AP will die. Timing is critical –AP exiting the block must find excitable tissue to propagate. If it can re-excite the tissue, a circular pathway of high frequency impulses (tachyarrhythmia) will become the source of APs that spread throughout a region of the heart (ventricle) or the entire heart.

Notes Anti-arrhythmics are also pro-arrhythmics Dangerous side effects

Vaughan-Williams Classification Mechanism Example I Na channel blockers Membrane Stabilisers Lignocaine II Beta Blockers Metoprolol III K channel blockers Amiodarone IV Ca channel blockers Verapamil Other Digoxin. Adenosine. MgSO4. Atropine Links AA drugs to a MOA Not all drugs are included – Some commonly used Some drugs overlap classes - Sotalol

Class I =sodium channel blockers Interfere with the sodium channel Grouped by what effect they have on the Na+ channel, and what effect they have on cardiac action potentials 1A lengthens the action potential (right shift) 1B shortens the action potential (left shift) 1C does not significantly affect the action potential (no shift) Called Membrane Stabilizing agents. The 'stabilizing' is the word used to describe the decrease of excitogenicity of the plasma membrane which is brought about by these agents

Sodium channels physiology Deactivated (closed) Activated (open) inactivated (closed) .

(Na+) channel block (intermediate association/dissociation) Quinidine Mechanism of action Members Uses Class 1A (Na+) channel block (intermediate association/dissociation) Quinidine Procainamide Disopyramide Ventricular arrhythmias Prevention of paroxysmal recurrent atrial fibrillation (triggered by vagal overactivity) procainamide in Wolff-Parkinson-White syndrome Class 1B (Na+ channel) block (fast association/dissociation) Lidocaine Phenytoin Mexiletine treatment and prevention during and immediately after myocardial infarction, though this practice is now discouraged given the increased risk of asystole ventricular tachycardia atrial fibrillation Class 1C (Na+channel) block (slow association/dissociation) Flecainide Propafenone Moricizine prevents paroxysmal atrial fibrillation treats recurrent tachyarrhythmias of abnormal conduction system contraindicated immediately post-myocardial infarction.

Class I A Agents Also blocks K Ch Block open ACTIVATED Na channels Greater affinity for rapidly firing channels Slow phase 0 depolarisation - upstroke of AP Lengthen APD and ERP. Cause torsades de pointes Also blocks K Ch Prolong QRS duration on ECG Uses: Ventricular and supraventricular tachycardia Anticholinergic S/E They can cause AV block

Class Ia agents Disopyramide: Quinidine: Procainamide : Negative Inotrope Worsening of heart failure Strong anticholinergic SE Quinidine: Also antimalarial Procainamide : Cause systemic lupus erythromatous

Class Ia effect on action potential

Class I B Agents Block INACTIVATED Na channels Slow phase 0 depolarisation- Slows upstroke of AP Shorten APD and ERP Ratio ERP/APD is increased Greater affinity for ischaemic tissue that has more inactivated channels, little effect on normal cells – dissociates quickly (0.5sec)

Class Ib agents Lignocaine(lidocaine): Phenytoin Also local anasthetic Used Ventricular arrhythemias in MI pts Not the best now we use amiodarone IV Administration Side effects CNS SE:convulsions,slurred speech Induce arrhythmia Phenytoin Also anticonvulsant Drug of choice in treatment of digoxin toxicity Side effects: CNS SE:convulsions,slurred speech,nystagmus Gingival hyperplasia

Class Ib effect on action potential

Class I C Agents Block Na channels. Most potent Na channel block Dissociate very slowly (10-20 sec) Strongly depress conduction in myocardium Slow phase 0 depolarisation - upstroke of AP No effect on APD No effect on QRS

Class Ic agents Flecainide: Propafenone Used for life threatening ventricular arrhythemia Last line treatment Side effects Induce arrhythmia Propafenone Used for ventricular arrhythmia and supraventricular arrhythmia Has beta blockage activity Beta blockage side effects

Class Ic effect on action potential

Class II Agents Beta Blockers - Block B1 receptors in the heart Decrease Sympathetic activity Non-Nodal Tissue: Increase APD and ERP SA and AVN: Decrease heart rate Decrease conduction velocity (Block re-entry) Inhibit aberrant PM activity

Class II agents Propranolol Atenolol Esmolol Metoprolol Use: Prevent arrhythmias after MI Used for supraventricular and ventricular arrhythmia Esmolol is used for acute surgical arrhythemias

ATENOLOL Non-selective B-Blocker (B1 and B2) Indications: Convert or Slow rate in SVTs 2nd line after Adenosine/Digoxin/Diltiazem IV atenolol 5 mg over 5 minutes Repeat to maximum 15 mg. 50 mg PO BID if IV works Contraindiactions: Asthma CCF. Poor EF. High degree heart block. Ca channel blockers. Cocaine use.

Class III Agents Anti-Fibrillatory agents. Block K channels Prolong repolarisation Prolong APD and ERP Useful in Re-Entry tachycardias

Class III agents Sotalol Amiodarone Uses: supraventricular and ventricular arrhythmia

Amiodarone Related structurally to thyroid hormone Exhibits properties of class I to IV but it is predominantly type III Taken PO or IV Side effects: Photosensitivity Thyroid disorders Pulmonary alveolitis Neuropathy Blue skin discoloration caused by iodine Corneal microdeposits Hepatocellular necrosis

Class III effects on action potential

Class IV Agents Calcium Channel Blockers Bind to L-type Ca channels in Vascular Smooth Muscle, Cardiac nodal & non-nodal cells Decrease firing rate of aberrant PM sites Decrease conduction velocity Prolong repolarisation

VERAPAMIL Narrow complex tachycardias Terminates PSVT/SVT Rate control in AFib/Aflutter NOT WPW or VT or high degree block NOT with BBlockers Negative Inotropy Vasodilation – Hypotension Diltiazem less adverse effects

What does Adenosine Do? Purine nucleoside Acts on A1 adenosine receptors Opens Ach sensitive K channels Inhibits Ca in current – Suppresses Ca dependent AP (Nodal) Increases K out current – Hyperpolarisation Inhibits AVN > SAN Increases AVN refractory period

ADENOSINE Interrupts re-entry and aberrant pathways through AVN – Diagnosis and Treament Drug for narrow complex PSVT SVT reliant on AV node pathway NOT atrial flutter or fibrillation or VT Contraindications: VT – Hypotension and deterioration High degree AV block Poison or drug induced tachycardia Bronchospasm but short DOA

What does Digoxin Do? Reduces ventricular response to SVTs Cardiac glycoside Blocks Na/K ATPase pump in heart Less ECF Na for Na/Ca pump Increased IC Ca Inotropic: Increases force of contraction AVN increased refractoriness Decreases conduction through AVN and SAN Negative chronotrope: Slows HR Reduces ventricular response to SVTs

Magnesium Mechanism of action is unknown Used for treatment of torsades de pointes Side effects: Bradycardia Respiratory paralysis Flushing Headache